Fusion Protein Biosensor for Signal-to-Noise Ratio in Neuromodulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring and modulating cell signaling, particularly in neuromodulation mapping, suffer from poor signal-to-noise ratios due to ligand-independent background signals, limiting their application in studying phasic neuromodulatory states and complex neuronal networks.
Innovation Solution
A nucleic acid molecule encoding a fusion protein with a transmembrane domain linked to a biosensor, an effector-activating module, a protease cleavage site sterically occluded until stimulated, and an effector molecule, enabling precise light-inducible and calcium-dependent gene expression for improved spatiotemporal resolution and signal-to-noise ratio.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods for monitoring cell signaling are used, then gene expression can be detected, but signal-to-noise ratio is poor due to ligand-independent background signals
Solution Approach 1:
The fusion protein is segmented into multiple functional domains: a transmembrane domain, a biosensor domain, a protease cleavage site, and an effector domain. This segmentation allows the system to separate the signal detection function from the gene expression activation function, enabling precise control and reducing background noise through spatial and functional separation of components.
Solution Approach 2:
The biosensor is positioned to preemptively detect ligand binding before triggering downstream signaling. The sterically occluded protease cleavage site is pre-configured in an inactive state, requiring specific biosensor activation by ligand binding to become accessible. This preliminary detection mechanism ensures that gene expression is activated only upon genuine ligand binding events, eliminating ligand-independent background signals.
2Measurement precision
If conventional signaling monitoring methods are used, then cellular responses can be observed, but spatiotemporal resolution is insufficient for studying phasic neuromodulatory states
Solution Approach 1:
The patent replaces conventional slow biochemical detection methods with a light-inducible optogenetic system. The biosensor utilizes light-sensitive domains (such as CRY2-CIB1 or PHR-CRY2 pairs) that can be activated by specific wavelengths of light, enabling rapid and precise temporal control. This optical control mechanism substitutes traditional mechanical or chemical activation methods, achieving superior spatiotemporal resolution for monitoring phasic neuromodulatory states in real-time.
3Speed
If the protease cleavage site is always accessible, then effector activation is rapid, but signal specificity is reduced due to constitutive activity
Solution Approach 1:
The protease cleavage site is designed with dynamic accessibility - it transitions from a sterically occluded inactive state to an accessible active state only upon biosensor activation by ligand binding. This dynamic control mechanism ensures that the effector is activated rapidly when needed (maintaining speed) while preventing constitutive activity (maintaining specificity). The system adapts its conformational state based on ligand binding events, achieving both rapid response and high signal fidelity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a high spatiotemporal resolution and reduced signal-to-noise ratio, enabling precise monitoring and modulation of cell signaling, particularly in mammalian brains, and allows for the investigation of neuromodulation codes in complex neuronal networks.
Implementation Method 1
a third biosensor comprising a protease cleavage site, wherein the protease cleavage site is sterically occluded in the absence of a stimulus for said third biosensor and wherein the protease cleavage site becomes accessible in the presence of said stimulus
Implementation Method 2
a nucleic acid sequence encoding a first part of a protease, wherein said first part of the protease is capable of interacting with a second part of said protease to form an active form of said protease
Data Source
AI summary
The present invention relates to a nucleic acid molecule encoding a fusion protein, wherein the nucleic acid molecule comprises: (a) a first nucleic acid sequence encoding a first biosensor, wherein said first biosensor is a first molecule capable of interacting with a second molecule; (b) a second nucleic acid sequence encoding an effector-activating module, wherein the effector-activating module comprises a nucleic acid sequence encoding a first part of a protease, wherein said first part of the protease is capable of interacting with a second part of said protease to form an active form of said protease; (c) a third nucleic acid sequence encoding a third biosensor comprising a protease cleavage site, wherein the protease cleavage site is sterically occluded in the absence of a stimulus for said third biosensor and wherein the protease cleavage site becomes accessible in the presence of said stimulus.